Unlock instant, AI-driven research and patent intelligence for your innovation.

Use of chlorogenic acid in preparing medicine with liver protective efficiency

A technology of chlorogenic acid and protection, applied in the field of chlorogenic acid, can solve problems such as no report

Inactive Publication Date: 2007-01-24
SICHUAN JIUZHANG BIO TECH CO LTD
View PDF0 Cites 14 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

Nevertheless, we further found that it also has many other new medical effects through pharmacological experiments, and these new medical effects have never been reported in the existing literature.

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Examples

Experimental program
Comparison scheme
Effect test

experiment example 1

[0009] Experimental Example 1 Protective effect of chlorogenic acid on carbon tetrachloride-induced liver injury in rats

[0010] 1 Experimental method

[0011] Seventy-two healthy SD rats were randomly divided into 6 groups according to sex and body weight. Administered respectively by group, each mouse of negative group and model group intraperitoneally injects normal saline 1ml / 100g body weight, and each mouse of positive group (bifendate) is given 1.5% concentration bifendate 1ml / 100g body weight (150mg / kg ), and the remaining three groups were given 1ml / 100g body weight (dose 20, 10 and 5mg / kg) by intraperitoneal injection of 1ml / 100g body weight (dose 20, 10 and 5mg / kg) to each rat of each group with 0.2%, 0.1% and 0.05% chlorogenic acid crude drug liquid respectively. The above 6 groups were administered once a day for 7 days in a row. On the 7th day, the body weight of the surviving animals was weighed. One hour after the last administration, all mice in the other gro...

experiment example 2

[0018] Experimental example 2 Protective effect of chlorogenic acid on galactosamine-induced liver damage in mice

[0019] 1 Experimental method

[0020] Seventy-two healthy Kunming mice were randomly divided into 6 groups according to sex and body weight. Administration is divided into groups respectively, each rat of negative group and model group is intraperitoneally injected normal saline 0.4ml / 20g body weight, and each rat of positive group (bifendate) is fed with 0.75% concentration bifendate 0.4ml / 20g body weight (150mg / kg), and the remaining three groups were given 0.4ml / 20g body weight (dose 20, 10 and 5mg / kg) by intraperitoneal injection of 0.4ml / 20g body weight (dose 20, 10 and 5mg / kg) respectively with chlorogenic acid liquid medicine of 0.1%, 0.05% and 0.025%. Each mouse in the above 6 groups was administered once a day for 7 consecutive days. On the 7th day, the body weight of the surviving animals was weighed. One hour after the last administration, except the...

experiment example 3

[0026] Experimental example 3 Protective effect of chlorogenic acid on mouse liver injury caused by duck liver virus

[0027] 1 Experimental method

[0028] One-day-old ducklings hatched from eggs produced by healthy adult Peking ducks were inoculated intraperitoneally with 0.1 ml of duck hepatitis B virus DNA (DHBV DNA) positive virus serum. One week after the inoculation, the blood was drawn from the external jugular vein, and the positive ducks were screened out by dot hybridization with digoxin-labeled DHBV DNA probes, and the ducks were bred until they were 2 weeks old as experimental animals. As the normal control group, ducks of the same age that were not infected with the virus were used. DHBV-DNA positive ducks were randomly divided into 5 groups, which were administered intraperitoneally every morning. Administer once a day for 1 month. Measure serum ALT, AST (Rei's method) after 1 month of medication.

[0029] 2 Experimental results

[0030]

group...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The present invention discloses the use of chlorogenic acid in preparing medicine for protecting liver and treating liver diseases alone or together with other medicine component.

Description

technical field [0001] The invention relates to a new application of chlorogenic acid, in particular to the application of chlorogenic acid in the preparation of drugs with liver protection effect. Background technique [0002] Chlorogenic acid is widely found in various medicinal plants such as honeysuckle, and its chemical structure has been clearly studied. Some people have conducted medicinal research on it, and it has been reported that chlorogenic acid can be used to treat diseases such as tumors. Nevertheless, we further found that it also has many other new medical effects through pharmacological experiments, and these new medical effects have never been reported in the existing literature. Contents of the invention [0003] The object of the present invention is to provide the use of chlorogenic acid in preparing medicine with liver protection effect. [0004] After experiments, it was found that chlorogenic acid has the effect of protecting the liver, and can tr...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Applications(China)
IPC IPC(8): A61K31/216A61P1/16
CPCA61K31/216A61P1/16A61P31/12
Inventor 张洁徐小平张舒包旭张亮雍智全李鑫泉
Owner SICHUAN JIUZHANG BIO TECH CO LTD